Accepted for Publication: July 26, 2013.
Published Online: January 13, 2014. doi:10.1001/jamaneurol.2013.4551.
Study concept and design: Pranzatelli, Lennon, McKeon.
Acquisition of data: Philipps, Alisanski, Pranzatelli, Clardy, McKeon.
Analysis and interpretation of data: Alisanski, McKeon.
Drafting of the manuscript: McKeon.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, and material support: Philipps, Clardy, Lennon.
Study supervision: McKeon.
Conflict of Interest Disclosures: Dr Philipps has received compensation from Lundbeck Pharmaceuticals within the past year for consultative work. Dr Pranzatelli receives research support from the Spastic Paralysis Research Foundation (Illinois–Eastern Iowa District), Kiwanis International, Ronald McDonald Charities of Central Illinois, and Questcor Pharmaceuticals. Dr Lennon receives research support as grant RO1-NS065829 from the National Institutes of Health and is named inventor on 2 patent applications filed by Mayo Foundation for Medical Education and Research that relate to neuromyelitis optica (NMO; aquaporin 4 [AQP4]) antibody and its application to cancer and functional assays for detecting AQP4-IgG. A patent issued for technology related to NMO-IgG testing has been licensed to a commercial entity. Dr Lennon and Mayo Clinic have received royalties that exceed the federal threshold for significant financial interest from licensing of this technology and have rights to receive future royalties. Serological testing for neural autoantibodies is offered on a service basis by Mayo Collaborative Service, Inc, an agency of Mayo Foundation. Neither Dr Lennon nor her laboratory benefit financially from this testing. Dr McKeon receives research support from the Guthy-Jackson Charitable Foundation. No other disclosures were reported.